These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1844700)

  • 1. Selecting combinations of chemotherapeutic drugs to maximize dose intensity.
    Simon R; Korn EL
    J Biopharm Stat; 1991; 1(2):247-59. PubMed ID: 1844700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selecting drug combinations based on total equivalent dose (dose intensity).
    Simon R; Korn EL
    J Natl Cancer Inst; 1990 Sep; 82(18):1469-76. PubMed ID: 2118188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combination phase I trials].
    Masuda N
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):219-25. PubMed ID: 8611050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New approaches to adjuvant chemotherapy for breast cancer.
    Hudis C
    Pharmacotherapy; 1996; 16(3 Pt 2):88S-93S. PubMed ID: 8726587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations.
    Mandrekar SJ; Cui Y; Sargent DJ
    Stat Med; 2007 May; 26(11):2317-30. PubMed ID: 17016867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response surface methodology and the design of clinical trials for the evaluation of cancer chemotherapy.
    Carter WH
    Cancer Treat Rep; 1985 Oct; 69(10):1049-53. PubMed ID: 4042084
    [No Abstract]   [Full Text] [Related]  

  • 7. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
    Tamura K
    Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
    [No Abstract]   [Full Text] [Related]  

  • 8. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.
    Frei E; Elias A; Wheeler C; Richardson P; Hryniuk W
    Clin Cancer Res; 1998 Sep; 4(9):2027-37. PubMed ID: 9748116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of dose and dose intensity in lung cancer chemotherapy.
    Murray N
    Semin Oncol; 1987 Dec; 14(4 Suppl 4):20-8. PubMed ID: 2825357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are we moving towards continuous treatment in small cell lung cancer (SCLC)?
    Van Zandwijk N
    Anticancer Res; 1994; 14(1B):309-11. PubMed ID: 8166473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-intensive chemotherapy in advanced adult soft tissue sarcoma.
    Verma S; Bramwell V
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):201-15. PubMed ID: 12113242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Alternating non-cross resistant multi-drug chemotherapy against malignant lymphoma (CAMBO-VIP)--consideration of the dose intensity].
    Hirano M; Okamoto M; Maruyama F; Shinkai K; Miyazaki H; Ezaki K
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):1982-8. PubMed ID: 2221923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel and doxorubicin in metastatic breast cancer.
    Gehl J; Boesgaard M; Paaske T; Jensen BV; Dombernowsky P
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):35-8. PubMed ID: 8996596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design issues in dose-finding Phase I trials for combinations of two agents.
    Fan SK; Venook AP; Lu Y
    J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.
    Sledge GW; Robert N; Sparano JA; Cobeligh M; Goldstein LJ; Neuberg D; Rowinsky E; Baughman C; McCaskill-Stevens W
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):15-8. PubMed ID: 7939756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.
    Potter DM
    J Biopharm Stat; 2006; 16(5):579-604. PubMed ID: 17037260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant breast cancer therapy: current status and future strategies--growth kinetics and the improved drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):1-4. PubMed ID: 10203263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.